The platform, based on the firm's Hi-C technology, is designed to assembly viral genomes from metagenomic samples and associate them with their microbial hosts.
The grant will fund an investigation into long noncoding RNA and the role it plays in differing prognoses between Black and white breast cancer patients.
The company's DETECTR disease detection platform will be used to help develop the technology and optimize the CRISPR enzymes used in the point-of-care device.
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.